Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...

Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.

The expression of tissue factor (TF) is limited in normal tissues to the perivascular compartment where it acts as the receptor for the serin protease factor VIIa. This signaling axis triggers the ...